CAS: 82571-53-7; (E)-3-(4-((1H-Imidazol-1-yl)Methyl)Phenyl)Acrylic Acid

该化合物是一个强大的tromboxane A2 受体对抗者,它表现出了抗板状物的特性,有效地抑制了小板块的聚集,并减少了Thronbus的形成,同时又不影响出血时间或凝固参数. 这一特征使得 Ozagrel 成为管理与过度血凝结有关的情况的有吸引力的选择.

英文名称(E)-3-(4-((1H-Imidazol-1-yl)Methyl)Phenyl)Acrylic Acid
中文名称奥扎格雷
IUPAC名称(E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylic acid
其它别名(E)-3-[4-(1H-Imidiazol-1-ylmethyl)phenyl]-2-propenic acid
CAS编号82571-53-7
MFCD编号:MFCD00868231
FDA UNII编号:L256JB984D
分子式:C13H12N2O2
分子量:228.25
产品CID: 1816266
同类组份化合物CAS189224-26-8 (sodium)82571-53-7 (free base)74003-18-2 (HCl)
产品分类原料药 → 血液系统用药 → 抗凝血药及抗血小板药

相似结构搜索
InChIKey: SHZKQBHERIJWAO-AATRIKPKSA-N
InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+…
计算化学: 氢键受体数3.0氢键供体数1.0可旋转键数4.0

物理性质

熔点223-224°
沸点468.0±25.0 °C(预测)
闪点236.8 °C
密度1.17±0.1 g/cm3(预测)
pKa:4.43±0.10(预测)
PSA:55.12
LogP:2.0292
折射率1.593
蒸汽压1.47E-09 mmHg at 25 °C
溶解性DMSO: 50 mg/mL (219.06 Mm; Need Ultrasonic)
外观形态白色至类白色粉末
储存条件密封, 常温干燥保存
产品应用奥扎格雷(82571-53-7)的用途:1.强力血栓素合成酶抑制剂.通过抑制血栓素合成酶,降低体内血栓素A2(TXA2),并促进前列环素(PGl2)的生成,以对抗血小板的聚集和脑血管的痉挛,而对环氧化酶等其它花生四烯酸代谢酶几乎无影响.2.临床用于蛛网下腔出血术后的脑痉挛以及伴随脑痉挛的脑缺血症状,及脑血栓症急性期伴随的运动障碍的改善.奥扎格雷(82571-53-7)的作用:1.可抑制TXA2合成酶,具有抗血小板聚集和解除血管痉挛的作用.2.临床上用于蛛网膜下腔出血手术后血管痉挛及其并发脑缺血症状的改善.
性质描述奥扎格雷(82571-53-7)的化学性质:从乙醇-乙醚得棱状结晶,熔点223~224°C.盐酸奥扎格雷:从乙醇-乙醚结晶,熔点214~217°C.奥扎格雷钠:白色结晶或结晶性粉末,无臭,味酸苦.易溶于水,溶于甲醇,几不溶于乙醇,丙酮或乙醚.急性毒性LD50雄,雌小鼠,雄,雌大鼠(mg/kg):1940,1580,1150,1300静脉注射;3800．3600．5900,5700 口服;2450,2100,2300,2250皮下注射.

上下游产品

ethyl (E)-3-[4-(imidazol-1-ylmethyl)phenyl]acrylate cis-ozagrel ethyl (E)-4-(bromomethyl)cinnamate 4-(1-imidazolylmethyl)cinnamic acid hydr°Chloride

合成工艺路线路线简述

合成目标产物 Ozagrel 主要起始原料 Ozagrel Hydrochloride
956932-46-0 = 82571-53-7
反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 2 H,50 °C1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5
标题:Process For Synthesizing Ozagrel
作者:Xue,Xuming; Et Al
参考文献:Huagong Jinzhan 日期:2009 卷标:28(11) 页码:2024-2027]

956932-46-0 = 82571-53-7
反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 3 H,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5,Rt
标题:Synthesis And Crystal Structure Of A Three-Dimensional Cobalt Coordination Polymer Assembled By Ozagrel Ligands
作者:Nie,Xu-Liang; Et Al
参考文献:Chinese Journal Of Structural Chemistry 日期:2015 卷标:34(1) 页码:117-122]

72459-46-2 = 82571-53-7
反应条件:1.1 Reagents: Calcium Carbonate,Potassium Carbonate Catalysts: Palladium,β-Cyclodextrin,2-Hydroxypropyl Ethers Solvents: Dimethylformamide,Water; 2 H,120 °C2.1 Reagents: Sodium Hydroxide Solvents: Water; 1 H,60 °C; 60 °C -> Rt2.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5,Rt
标题:A New Synthetic Model Of Ozagrel
作者:Zhang,Lijuan; Et Al
参考文献:Zhongguo Yiyao Gongye Zazhi 日期:2015 卷标:46(7) 页码:674-676]

79-20-9 + 104-87-0 = 82571-53-7
反应条件:1.1 Reagents: Sodium Solvents: Ethanol; Rt -> 0 °C1.2 3 H,0 °C1.3 Reagents: Acetic Acid Solvents: Water2.1 Reagents: Benzoyl Peroxide,N-Bromosuccinimide Solvents: Carbon Tetrachloride; 6 H,Reflux3.1 Reagents: Potassium Hydroxide Solvents: Dimethylformamide; 0.5 H,Rt3.2 Solvents: Dimethylformamide; 5 H,Reflux4.1 Reagents: Sodium Hydroxide Solvents: Water; 2 H,50 °C4.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5
标题:Process For Synthesizing Ozagrel
作者:Xue,Xuming; Et Al
参考文献:Huagong Jinzhan 日期:2009 卷标:28(11) 页码:2024-2027]

956932-46-0 = 82571-53-7
反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 1 H,60 °C; 60 °C -> Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5,Rt
标题:A New Synthetic Model Of Ozagrel
作者:Zhang,Lijuan; Et Al
参考文献:Zhongguo Yiyao Gongye Zazhi 日期:2015 卷标:46(7) 页码:674-676]

20754-20-5 = 82571-53-7
反应条件:1.1 Reagents: Benzoyl Peroxide,N-Bromosuccinimide Solvents: Carbon Tetrachloride; 6 H,Reflux2.1 Reagents: Potassium Hydroxide Solvents: Dimethylformamide; 0.5 H,Rt2.2 Solvents: Dimethylformamide; 5 H,Reflux3.1 Reagents: Sodium Hydroxide Solvents: Water; 2 H,50 °C3.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5
标题:Process For Synthesizing Ozagrel
作者:Xue,Xuming; Et Al
参考文献:Huagong Jinzhan 日期:2009 卷标:28(11) 页码:2024-2027]

288-32-4 + 589-15-1 = 82571-53-7
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Acetone; 1 H,Rt2.1 Reagents: Calcium Carbonate,Potassium Carbonate Catalysts: Palladium,β-Cyclodextrin,2-Hydroxypropyl Ethers Solvents: Dimethylformamide,Water; 2 H,120 °C3.1 Reagents: Sodium Hydroxide Solvents: Water; 1 H,60 °C; 60 °C -> Rt3.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5,Rt
标题:A New Synthetic Model Of Ozagrel
作者:Zhang,Lijuan; Et Al
参考文献:Zhongguo Yiyao Gongye Zazhi 日期:2015 卷标:46(7) 页码:674-676]

= 82571-53-7
反应条件:1.1 Reagents: 1,3-Dibromo-5,5-Dimethylhydantoin Catalysts: Benzoyl Peroxide Solvents: Dichloromethane; 6 H,Reflux2.1 Reagents: Potassium Carbonate Solvents: Acetone; 1 H,Rt3.1 Reagents: Calcium Carbonate,Potassium Carbonate Catalysts: Palladium,β-Cyclodextrin,2-Hydroxypropyl Ethers Solvents: Dimethylformamide,Water; 2 H,120 °C4.1 Reagents: Sodium Hydroxide Solvents: Water; 1 H,60 °C; 60 °C -> Rt4.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 5,Rt
标题:A New Synthetic Model Of Ozagrel
作者:Zhang,Lijuan; Et Al
参考文献:Zhongguo Yiyao Gongye Zazhi 日期:2015 卷标:46(7) 页码:674-676

乙基(2E)-3-[4-(溴甲基)苯基]丙烯酸酯置于sodium Hydroxide,Sodium Hydride体系中,化学反应 3.0H,反应生成奥扎格雷
参考文献:血栓烷合成酶的高度选择性抑制剂.1.咪唑衍生物.
标题:血栓烷合成酶的高度选择性抑制剂.1.咪唑衍生物.
摘要:研究了咪唑衍生物作为血栓烷(tx)合成酶抑制剂的构效关系.将各种取代基(例如一个或两个甲基,卤原子,亚甲基,不饱和键或亚苯基)引入1-(7-羧基庚基)的含羧基侧链的α位或其他位置发现咪唑(15)增强了抑制效力.带有亚苯基的侧链的长度对于在8.5-9.0 A范围内对tx合成酶的抑制效力而言是最佳的.在测试的咪唑衍生物中,1-(7-羧基-7-甲基-2-辛基)咪唑(47),4-[3-(1-咪唑基)-丙基]苯甲酸(50),
DOI:10.1021/jm00142A005

海关参考信息

2901210000-乙烯
2901220000-丙烯
2902300000-甲苯
2902500000-苯乙烯
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:KR-101513003-B1
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy compositions and applications

专利号:US-10814013-B2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:AU-2007308022-A1
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

其他信息查阅

杭州国瑞生物科技有限公司

网址: http://www.guoruibio.com
电话:0571-85183519:0571-85182680👤
浙江杭州市滨江区江二路400号和瑞科技园S-1幢1502室

⚠️ 未注册 · 未认证企业

备注: 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别. 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

济南中科一通化工有限公司

网址: http://www.jnzkyt.com
电话: 0086 (531) 8865-8009👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

中孚药业股份有限公司

网址: http://www.zhongfupharm.com
电话: 86-536-2206826,2206827,2206829👤

⚠️ 未注册 · 未认证企业

济南宏方德医药科技有限公司

网址: http://www.hfdchem.com
电话: 531-88870908👤

⚠️ 未注册 · 未认证企业

吉林省西点药业科技发展股份有限公司

网址: http://www.xidianyy.com
电话: 0432-65888200/0432-65888299👤

⚠️ 未注册 · 未认证企业

丹东医创药业有限责任公司

网址: http://www.ddycyy.com
电话: 0415-3125313/0415-3124267👤

⚠️ 未注册 · 未认证企业

重庆圣华曦药业股份有限公司

网址: http://www.shenghuaxi.com
电话: 023-62515566👤
地址：安徽省太和县镜湖东路1号

⚠️ 未注册 · 未认证企业

江苏弘惠医药有限公司

网址: http://www.jshonghui.com.cn
电话: 025-83308303👤

⚠️ 未注册 · 未认证企业

江苏海慈生物药业有限公司

网址: https://www.yangzijiang.com/
电话: 15827492278👤

⚠️ 未注册 · 未认证企业

天津太平洋化学制药有限公司

网址: http://www.tj-pacific.com
电话: 022-88515355👤

⚠️ 未注册 · 未认证企业

瑞阳制药有限公司

网址: http://www.reyoung.cn
电话: 400-612-3458👤

⚠️ 未注册 · 未认证企业

济南嘉瑞药业有限公司

网址: http://www.jnjiarui.com
电话: 0531-88015231👤

⚠️ 未注册 · 未认证企业

山东诚汇医药集团有限公司

网址: http://www.jnchsd.com
企业联系电话：0531-58897025-13589078718👤
地址:济南市高新技术开发区开拓路2350号

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

济南朗化化工有限公司

网址: http://www.lhchem.cn
企业联系电话：0531-85906691;18660816586👤
地址:山东省济南市天桥区无影山中路48号

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Park SI, Park SK, Jang KS, Han YM, Kim CH, Oh SJ. Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. Brain Res. 2015 Mar 2;1599:85-92. doi: 10.1016/j.brainres.2014.12.051. Epub 2014 Dec 31. Epub 2013 Mar 1. doi: 10.1179/1743132812Y.0000000022. doi: 10.1371/journal.pone.0088440. eCollection 2014.
6: Xu SH, Yin MS, Liu B, Chen ML, He GW, Zhou PP, Cui YJ, Yang D, Wu YL. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion. Hum Exp Toxicol. 2016 Jul 6. pii: 0960327116657401. [Epub ahead of print] Epub 2007 Jul 4. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.002. Epub 2012 May 22. Chinese. doi: 10.1159/000210190. Epub 2009 Mar 26.

合成参考文献

参考文献:10.1097/00007890-199610150-00001
摘要:Matsumoto S, Kuroda Y, Fujita H, Tanioka Y, Sakai T, Hamano M, Kim Y, Suzuki Y, Ku Y, Saitoh Y. Extending the margin of safety of preservation period for resuscitation of ischemically damaged pancreas during preservation using the two-layer (University of Wisconsin solution/perfluorochemical) method at 20 degrees C with thromboxane A2 synthesis inhibitor OKY046. Transplantation. 1996 Oct 15;62(7):879–83. doi: 10.1097/00007890-199610150-00001.
参考文献:10.1097/00024382-199609000-00005|10.1097/00024382-199609010-00005
摘要:Enzan K, Kurosawa S, Yoshioka N, Inaba H. THROMBOXANE RATHER THAN PLATELET ACTIVATING FACTOR MEDIATES PULMONARY VASOCONSTRICTION AFTER ANTIGEN CHALLENGE IN RABBITS. Shock. 1996 Sep;6(3):183–7. doi: 10.1097/00024382-199609000-00005.
参考文献:10.1016/s0024-3205(01)01229-2
摘要:Satoh S, Utsunomiya T, Tsurui K, Kobayashi T, Ikegaki I, Sasaki Y, Asano T. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001 Aug 10;69(12):1441–53. doi: 10.1016/s0024-3205(01)01229-2.
参考文献:10.1016/j.jstrokecerebrovasdis.2018.03.016
摘要:Oguro H, Mitaki S, Takayoshi H, Abe S, Onoda K, Yamaguchi S. Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke. Journal of Stroke and Cerebrovascular Diseases. 2018 Aug;27(8):2175–81. doi: 10.1016/j.jstrokecerebrovasdis.2018.03.016.
摘要:Urade M, Izumi R, Iyobe T, Iwasa K, Masutani H, Tani T, Yabushita K, Hashimoto T, Kiriyama M, Shimizu K. Changes of thromboxane B2 level in experimental orthotopic liver transplantation in swines--the effect of warm ischemia and thromboxane A2 synthetase inhibition. Transplant Proc. 1992 Aug;24(4):1623–4.